Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CD19 and CD22 Targeted CAR-T Therapy by Chongqing Precision Biotech for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
CD19 and CD22 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase II for...
Data Insights
CD19 and CD22 Targeted CAR-T Therapy by Chongqing Precision Biotech for Unspecified B-Cell Lymphomas: Likelihood of Approval
CD19 and CD22 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase II for...